Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Sturchio

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Parkinsonism & Related Disorders|January 10, 2025
The α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathologyAlberto J Espay, Andrew J Lees, Francisco Cardoso, et al.
International Journal of Molecular Sciences|July 24, 2021
Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based NosologyLuca Marsili, Jennifer Sharma, Alberto J Espay, et al.
Journal of Alzheimer'S Disease : JAD|September 19, 2022
High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing MutationsAndrea Sturchio, Alok K Dwivedi, Tarja Malm, et al.
Orphanet Journal of Rare Diseases|October 29, 2025
Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Orphanet Journal of Rare Diseases|November 18, 2025
Correction: Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Parkinsonism & Related Disorders|May 8, 2021
Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseAndrea Pilotto, Alberto Imarisio, Francesca Conforti, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|October 21, 2020
The odyssey of complex neurogenetic disorders: From undetermined to positiveValeria Salinas, Patricia Vega, Luca Marsili, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
ACS Chemical Neuroscience|November 7, 2024
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein DepletionWanda Christ, Sebastian Kapell, Michal J Sobkowiak, et al.
BMC Neurology|June 3, 2014
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric studyChiara Pecori, Marta Giannini, Emilio Portaccio, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Parkinsonism & Related Disorders|January 10, 2025
The α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathologyAlberto J Espay, Andrew J Lees, Francisco Cardoso, et al.
International Journal of Molecular Sciences|July 24, 2021
Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based NosologyLuca Marsili, Jennifer Sharma, Alberto J Espay, et al.
Journal of Alzheimer'S Disease : JAD|September 19, 2022
High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing MutationsAndrea Sturchio, Alok K Dwivedi, Tarja Malm, et al.
Orphanet Journal of Rare Diseases|October 29, 2025
Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Orphanet Journal of Rare Diseases|November 18, 2025
Correction: Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypesSebile Kilavuz, Kerri-Lee Wallom, Ana Catarina Gomes Almeida Augusto Caçote, et al.
Parkinsonism & Related Disorders|May 8, 2021
Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseAndrea Pilotto, Alberto Imarisio, Francesca Conforti, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|October 21, 2020
The odyssey of complex neurogenetic disorders: From undetermined to positiveValeria Salinas, Patricia Vega, Luca Marsili, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
ACS Chemical Neuroscience|November 7, 2024
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein DepletionWanda Christ, Sebastian Kapell, Michal J Sobkowiak, et al.
BMC Neurology|June 3, 2014
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric studyChiara Pecori, Marta Giannini, Emilio Portaccio, et al.
Pageof 6